|
|
|
| |
Thrombotargets has developed and adapted to High Throughput Screening, a new family of biological assays capable to quantify simultaneously clot formation and clot lysis (HemostaScreen), total antioxidant capacity (OxidantScreen) and low-density lipoprotein modification (AtheroScreen). With these proven proprietary new HTS Platforms ( ), Thrombotargets is creating a continuously novel and promising pipeline of drug candidates.
|
|
|
|
|
|
|
We have developed High Throughput Screening Pathway Activity named BioplatformScreen TM. A new High Through Screening Phatway Activity (HTS-PA) family raise, HemostaBioplatformScreen, OxidantBioplatformScree and AtheroBioplatformScreen.
New biotech drug for deep vein thrombosis symptoms. TT-105 is a monoclonal antibody that shows high potency, good selectivity and demonstrates high efficacy in ex-vivo human experiments and in several in vivo animal models.
Innovative drug discovery and development group of biotech companies developing new medicines based on advances in recombinant DNA and molecular biology and small molecule drug technologies. The programs leverage the company hemostasis expertise and are focused on inherited and acquired Hemorrhagic and Thrombotic disorders.
|
|
|
|
